Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 581-586

  Akin, Mehmet ^a   Kavakli, Kaan ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

DDAVP; Diagnosis; Turkey; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING TIME; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GENETIC ANALYSIS; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; THROMBOCYTE AGGLUTINATION; TURKEY (REPUBLIC); VON WILLEBRAND DISEASE;

CLINICAL LABORATORY TECHNIQUES; COAGULANTS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HUMANS; TURKEY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 81755166550     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281046     Document Type: Article

References (26)

1. Sadler JE, Budde U, Eikenboom JCJ et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
2. Biron C, Mahieu B, Rochette A et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999 134 6 605-609
3. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987 69 2 454-459 (Pubitemid 17022013)
4. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993 123 6 893-898 (Pubitemid 23353251)
5. Yilmaz D, Karapnar B, Yeniay BS, Balkan C, Bilenolu B, Kavakl K. zmir'de von Willebrand Hastal skln belirtmeye yönelik epidemiyolojik çalma. [in Turkish] Ege Pediatri Bülteni. 2005 12 3 151-159
6. Gürsel T, Kavakl K, Aktulu G. Hemofili ve von Willebrand Hastalnda Tan ve Tedavi, Türk Hematoloji Dernei-Hemofili Alt Komitesi (Turkish Guideline). Istanbul, Turkey Rehberi 1999 2-5
7. World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2008. Available at: www.wfh.org/2/docs/Publications/ Statistics/2007-Survey-Report.pdf Accessed May 4, 2011
8. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006 32 5 456-471 (Pubitemid 44157383)
9. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 8 727-744 (Pubitemid 351158442)
10. Miller CH, Haff E, Platt SJ et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003 1 10 2191-2197
11. Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008 14 2 171-232 (Pubitemid 351343618)
12. James P, Lillicrap D. The role of molecular genetics in diagnosing von Willebrand disease. Semin Thromb Hemost 2008 34 6 502-508
13. Eikenboom J, Van Marion V, Putter H et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006 4 4 774-782
14. Budde U, Schneppenheim R, Eikenboom J et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008 6 5 762-771 (Pubitemid 351524536)
15. Favaloro EJ, Bonar R, Kershaw G et al, RCPA QAP in Haematology. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process. Haemophilia 2004 10 3 232-242 (Pubitemid 38584794)
16. Favaloro EJ, Thom J, Baker R, Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinolysis 2000 11 8 729-737 (Pubitemid 32010207)
17. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K, RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007 98 2 346-358 (Pubitemid 47250238)
18. Cattaneo M, Federici AB, Lecchi A et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999 82 1 35-39 (Pubitemid 29368770)
19. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen binding activity as coupled strategies. Semin Thromb Hemost 2006 32 6 566-576 (Pubitemid 44453018)
20. Akin M, Karapinar DY, Balkan C, Ay Y, Kavakli K. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children. Clin Appl Thromb Hemost 2010 May 11 (Epub ahead of print)
21. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HHDM. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Acta Haematol 2009 121 2-3 85-97
22. Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008 6 11 1999-2001; author reply 20022003
23. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001 7 2 180-189 (Pubitemid 32243801)
24. Favaloro EJ, Thom J, Patterson D et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009 123 6 862-868
25. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001 14 2 337-347 (Pubitemid 32677083)
26. Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002 28 2 111-132